-+ 0.00%
-+ 0.00%
-+ 0.00%

Genelux Presents Update on Olvi-Vec Phase 3 Ovarian Cancer Trial

PUBT·11/16/2026 21:45:08
Genelux Presents Update on Olvi-Vec Phase 3 Ovarian Cancer Trial
  • Genelux expects topline results from its pivotal Phase 3 Olvi-Vec trial in platinum-resistant or refractory ovarian cancer in the second half of 2026.
  • FDA alignment could support traditional approval without a confirmatory trial if progression-free survival improves meaningfully without an overall survival decline.
  • Pro forma cash totals approximately $16 million, providing runway into the first quarter of 2027.
  • Average quarterly operating cash burn is approximately $7 million; capital expenditures could reach approximately $6 million.
  • Additional dose-finding updates from systemic Olvi-Vec trials in recurrent small cell and non-small cell lung cancer are expected in 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genelux Corporation published the original content used to generate this news brief on November 16, 2026, and is solely responsible for the information contained therein.